AI
SNDX icon

Axiom Investors’s Syndax Pharmaceuticals SNDX Stock Holding History

Axiom Investors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-52,204
Closed -$641K – 149
2025
Q1 		$641K Sell
52,204
-1,020
-2% -$14.4K 0.01% 131
2024
Q4 		$704K Sell
53,224
-62,418
-54% -$1.07M 0.01% 130
2024
Q3 		$2.23M Buy
115,642
+20,502
+22% +$424K 0.02% 115
2024
Q2 		$1.95M Buy
95,140
+1,075
+1% +$22.5K 0.02% 119
2024
Q1 		$2.24M Buy
94,065
+7,890
+9% +$176K 0.02% 124
2023
Q4 		$1.86M Buy
86,175
+75,355
+696% +$1.16M 0.02% 121
2023
Q3 		$157K Sell
10,820
-19,290
-64% -$365K ﹤0.01% 132
2023
Q2 		$630K Buy
30,110
+1,915
+7% +$39.9K 0.01% 124
2023
Q1 		$595K Buy
+28,195
New +$701K 0.01% 125

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Axiom Investors's SNDX Position: Q2 2025 in Review

Axiom Investors sold out of Syndax Pharmaceuticals (SNDX) in Q2 2025, closing a stake of 52,204 shares — an estimated $641K sold.

Axiom Investors first reported a position in SNDX in Q1 2023 and held it in 9 quarters. The position peaked at $2.24M in Q1 2024. 216 funds tracked by Wall St. Rank hold SNDX as of Q2 2025.

  • Axiom Investors reported no remaining Syndax Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Axiom Investors sold 52,204 Syndax Pharmaceuticals shares in Q2 2025, an estimated $641K.
  • Axiom Investors first reported a position in Syndax Pharmaceuticals in Q1 2023 and held it in 9 quarters.
  • Axiom Investors's Syndax Pharmaceuticals position peaked at $2.24M in Q1 2024.
  • 216 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2025.

Based on Axiom Investors's 13F filing for Q2 2025, filed 7 Aug 2025.